Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics announced the enrollment of patients in Phase 1 clinical studies for FT538 and FT576 targeting relapsed/refractory multiple myeloma. Interim data from FT596 and FT516 for relapsed/refractory lymphoma show promising results with 71% and 73% objective response rates (ORR) respectively. Both FT596 and FT516 demonstrate differentiated safety profiles with low-grade adverse events. Financial results reveal total revenue of $14.2 million for Q3 2021, alongside R&D expenses of $53.1 million and cash reserves of $803.6 million as of September 30, 2021.

Fate Therapeutics announced that several presentations on their induced pluripotent stem cell (iPSC) product platform have been accepted for the 63rd American Society of Hematology Annual Meeting. The presentations will include updated clinical data for their cancer immunotherapies FT596 and FT516. FT596 achieved a 71% objective response rate in relapsed/refractory B-cell lymphoma patients, while FT516 achieved a 73% objective response rate. The treatments were well tolerated with no reported adverse events of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GVHD).

Fate Therapeutics (NASDAQ: FATE) announced a conference call for November 4, 2021, at 5:00 p.m. ET to discuss its third quarter 2021 financial results and corporate updates. Shareholders can join the call by dialing (877) 303-6235 domestically or (631) 291-4837 internationally, using conference ID 9459084. The live audio webcast will be available under the Events section of the company's website. Fate Therapeutics focuses on developing first-in-class cellular immunotherapies for cancer, leveraging its proprietary induced pluripotent stem cell technology.

Tentarix Biotherapeutics LP has secured a $50 million Series A investment, co-led by Versant Ventures and Samsara BioCapital. This funding will accelerate the development of its advanced biotherapeutic platform, designed for targeted, multifunctional therapies aimed at oncology and autoimmune diseases. The company focuses on creating antibody-based products that selectively activate immune responses, reducing adverse effects. Tentarix's lead program targets the IL2R gamma and beta receptors, showcasing potential breakthroughs in cell-specific therapies.

Fate Therapeutics, Inc. (NASDAQ: FATE) announced the acceptance of one oral and four poster presentations for its induced pluripotent stem cell (iPSC) platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021. The oral presentation will focus on preclinical data for FT536, a CAR NK cell candidate targeting MICA/B proteins. Additionally, poster presentations will cover advancements in CAR T cell therapies for solid tumors. Fate plans to submit an IND application for FT536 in Q4 2021.

Fate Therapeutics announces the publication of preclinical data on FT538, its engineered iPSC-derived NK cell product candidate, showcasing enhanced anti-tumor activity compared to traditional NK cells. The data reveal that FT538 demonstrates significant functional persistence and superior serial killing capability. Key innovations include the knockout of CD38 and the introduction of an IL-15/IL-15R fusion protein. FT538 is currently undergoing Phase 1 trials for treating acute myeloid leukemia and multiple myeloma, positioning it as a promising off-the-shelf therapy in cancer immunotherapy.

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on programmed cellular immunotherapies for cancer, announced its participation in several investor conferences in September 2021. Key events include the Virtual Wells Fargo Healthcare Conference on September 9, and the Morgan Stanley Annual Global Healthcare Conference on September 10. The company will also present at the H.C. Wainwright Conference on September 13, Baird’s Conference on September 15, Oppenheimer Summit on September 22, and Cantor Conference on September 29. Webcasts for these presentations can be found on their website.

Fate Therapeutics reported promising interim results from its FT596 and FT516 clinical programs for relapsed/refractory B-cell lymphoma. Notably, 71% of patients receiving FT596 achieved an objective response, with 50% achieving complete response (CR). In the FT516 program, 73% of patients achieved an objective response, with 55% reaching CR. Both treatments were well-tolerated, without significant adverse events. The company is initiating further dose-expansion cohorts and continuing to assess the treatment regimens' efficacy and safety.

Fate Therapeutics has made significant strides in the development of iPSC-derived therapies, with the first patient treated in the Phase 1 trial of FT819, a groundbreaking CAR T-cell therapy for relapsed/refractory ALL. Interim Phase 1 data for FT516 reveals that 73% of patients achieved objective responses in relapsed/refractory B-cell lymphoma. The company reported Q2 2021 revenue of $13.4 million, with R&D expenses at $48 million. Cash reserves stood at $845.1 million, indicating a solid financial position.